key: cord-0811071-5k724ii0 authors: Huette, Pierre; Beyls, Christophe; Guilbart, Mathieu; Haye, Guillaume; Najid, Fatim-Zahra; Mestan, Benjamin; Roger, Pierre-Alexandre; Dupont, Hervé; Abou-Arab, Osama; Mahjoub, Yazine title: Acute cor pulmonale in Covid-19 related ARDS: improvement with almitrine infusion. date: 2020-06-16 journal: JACC Case Rep DOI: 10.1016/j.jaccas.2020.06.011 sha: 628703bd177990ded5225e969bca01f779910e00 doc_id: 811071 cord_uid: 5k724ii0 ABSTRACT: Coronavirus disease-19 (Covid-19) related severe acute respiratory distress syndrome (ARDS) can lead to acute cor pulmonale (ACP). We report a case of ACP secondary to severe Covid-19 ARDS diagnosed with transesophageal echocardiography. Almitrine infusion allowed rapid enhancement of RV function as well as improvement in oxygenation. A 57-year-old woman was admitted at Amiens University hospital intensive care unit for severe ARDS 12 days following onset of cough, dyspnea and fever. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) of nasopharyngeal swab was positive for SARS-CoV-2. Chest CT-scan revealed peripheral ground-glass like opacities with superimposed interlobular and intralobular septal thickening (crazy paving). Patient condition deteriorated rapidly leading to mechanical ventilation with lung protective settings, prone positioning, deep sedation, neuromuscular blockade and inhaled nitric oxide (NO) at 10ppm. Despite these measures, she remained hypoxemic with a PaO 2 /FiO 2 ratio of 70. Following starting mechanical ventilation and sedation, mean arterial pressure (MAP) dropped to 60 mmHg. Norepinephrine was administered at the dose of 0.3 mcg.kg.min-1 to achieve a MAP target higher than 65 mmHg. Blood pressure rapidly reached 115/50 (71) mmHg. For patients in severe ARDS associated with hemodynamic impairment, local guidelines recommend close monitoring with pulmonary artery catheter (PAC) and transesophageal echocardiography (TEE). PAC and TEE revealed ACP with pulmonary hypertension. Medical history included only an overweight patient with a BMI of 38.9 kg.m -2 . The differential diagnosis included pulmonary embolism (PE) and RV infarction which were discounted later due to CT pulmonary angiogram not showing PE and normal ECG and normal high-sensitivity troponin. D-Dimer was 3.69 μg.ml -1 . Prior to commencing almitrine, arterial blood gas sample showed PaO 2 of 62.9 mmHg, PaCO 2 of 46.6 mmHg, Ph at 7.4, PaO 2 /FiO 2 ratio of 70 and lactate at 2.3 mmol. l -1 . Pulmonary artery catheter showed pulmonary artery pressure of 57/32 (42) mmHg with pulmonary vascular resistance at 5.9 Wood Units and pulmonary artery occlusion pressure of 7 mmHg. Right ventricular stroke work index (RVSWI) was 19.7 g/m/beat/m 2 (Normal range 8-10 g/m/beat/m2). TEE showed an ACP: the right ventricular to left ventricular area ratio was of 1 to 1 with septal dyskinesia ( Figure 1A) . In 2D conventional TEE, TAPSE was of 22 mm, tricuspid lateral annulus systolic velocity (S' wave) was of 15.2 cm. s -1 and RV fractional area change (FAC) was 43%. Speckle tracking based right ventricular two-dimensional strain was performed ( Figure 1B ). The RV global longitudinal strain (RVGLS) was -14.8% and RV free wall longitudinal strain was -17.3% (RVGSL normal value < -20%). Left ventricular ejection fraction (LVEF) was 65% without any valvular disease. Cardiac index (CI) was 2.6 l.min -1 .m -2 . Severe and prolonged hypoxemia can lead to organ dysfunction. Thus, the need for venovenous extra corporeal membrane oxygenation (ECMO) to improve oxygenation was considered for this patient with a very low PaO 2 /FiO 2 ratio of 70. As inhibition of hypoxic vasoconstriction was considered as a key point to explain severe hypoxemia related to Covid-19, decision was made to test almitrine treatment before starting ECMO (2) . However, because almitrine may increase RV afterload in a patient who already has an acute core pulmonale, a close RV monitoring was performed. Low dose of almitrine was given at an infusion rate of 4 mcg/kg/min via a central venous catheter. Complete hemodynamic, echocardiographic and biological assessment was repeated at 1, 2 and 12 hours following almitrine initiation (Table 1) . TEE video loops before and after almitrine infusion are presented in video 1 and video 2. Oxygenation improved significantly in the few hours following almitrine treatment (Table 2) . TEE showed an improvement of RV function: RV dilatation decreased (ratio at 0.75) and septal dyskinesia disappeared ( Figure 1C) . Moreover, RVGLS improved from -14.8% to -22.7% ( Figure 1D ). Twelve hours following almitrine infusion, RVSWI decreased from 19.7 g/m/beat/m 2 to 17.5 g/m/beat/m 2 . Clinical spectrum of SARS-CoV-2 related cardiovascular complication includes myocarditis, pericarditis, vasoplegia, right ventricular failure and acute coronary syndromes (1, 2) . In this case, we highlight the RV dysfunction related to SARS-CoV-2 infection. Pathophysiology of cardiovascular dysfunction related to SARS-CoV-2 remains unclear. One explanation is the recognition of human angiotensin-converting enzyme 2 (ACE2) by SARS-CoV-2. ACE 2 is used by the virus as a functional receptor to enter the cell (3). Moreover, ACE 2 receptor is not only present in lung alveolar cells but also in many extra pulmonary tissues especially heart, and vascular endothelium. Hence, direct viral effect on heart and vessels may lead to RV dysfunction. Another explanation is the impact of ARDS and mechanical ventilation on the RV. ACP is a well-known complication of ARDS despite a protective ventilation, with an incidence of 25%. Hence, ACP may be related to a high driving pressure leading to an increased RV afterload (4). Moreover, the patient was on norepinephrine that may increase RV afterload. Another explanation is that hypoxia could lead to RV dysfunction in its own right (5). SARS-CoV-2 related ARDS seems to be a non-typical ARDS as several patients had a preserved lung mechanics with high compliance despite severe hypoxemia. Some authors have hypothesized that SARS-CoV-2 related hypoxemia is due the impairment of hypoxic pulmonary vasoconstriction and dysregulation of pulmonary blood flow leading to an intra-pulmonary shunt responsible for the severe hypoxemia (6) . In a recently published report on a critically ill patient with SARS-CoV2 infection, the authors used Dual-energy chest CT. They found that a "considerable" pulmonary vessels dilatation and increased pulmonary blood flow surrounding areas of consolidation (7). Almitrine, a selective pulmonary vessel vasoconstrictor, was shown to increase arterial oxygenation via redistribution of pulmonary blood flow from shunt areas to pulmonary units with normal ventilation perfusion ratio (8) . Moreover, previous studies in the nineties showed that at low dose, the deleterious effect on pulmonary vascular resistance was neglectable especially when associated with nitric oxide (9) . Hence, we hypothesized that almitrine use in the case of SARS-CoV-2 atypical ARDS might be useful. In the present case, almitrine infusion was associated with RV function improvement and decrease in pulmonary vascular resistance. This is probably due not only to a better oxygenation but also to a better distribution of pulmonary vascular flow to aerated lung areas. Before almitrine infusion, we observed a high RVSWI with a normal-low range of CI suggesting a hemodynamic disconnection between RV and LV. The reduction in RV afterload by almitrine infusion resulted in an improvement in this disconnection (decreased RVSWI and improved CI). As Almitrine infusion could induce reversible lactic acidosis and hepatic dysfunction (10), careful monitoring of lactate and screening test for hepatic function were performed. We didn't observe those side effects. To our knowledge, this is first report of almitrine use for SARS-CoV-2 related ARDS showing an improvement in oxygenation. Nevertheless, monitoring of pulmonary artery pressure and RV function are important for safe use of almitrine. Before clinical use, well conducted studies with sufficient sample size are needed to demonstrate the efficacy of almitrine in SARS-CoV-2 associated severe ARDS. A randomized controlled trial is underway to address this issue: the AIRVM-COVID study (Clinical trial N° NCT04357457) will investigate the efficacy of intravenous almitrine in reducing the need for mechanical ventilation in patients with hypoxemic acute respiratory failure due to Covid-19-related Pneumonia. Almitrine was administered to the patient for 4 days resulting in consistent improvement in oxygenation and ventilator parameters. Right ventricular function remained stable. Weaning from mechanical ventilation occurred on day 16. The patient was discharged from ICU on day 26. Acute cor pulmonale may occur in patients suffering from SARS CoV-2 related ARDS. Echocardiography is the main tool to diagnose ACP in this context. In the present case, almitrine infusion was effective in improving oxygenation and the RV function. Table 2 Respiratory parameters before and after almitrine infusion To diagnose acute cor pulmonale (ACP) in patients with Severe acute respiratory coronavirus-2 (SARS-CoV-2) related acute respiratory distress syndrome To appreciate potential role of almitrine in improving oxygenation and right ventricular (RV) function Acute Cor Pulmonale in Critically Ill Patients with Covid-19 Cardiovascular Consequences and Considerations of Coronavirus Infection -perspectives for the cardiothoracic anesthesiologist and intensivist during the coronavirus crisis Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact Right ventricle dimensions and function in response to acute hypoxia in healthy human subjects Covid-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT Pharmacological interventions in acute respiratory distress syndrome Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitrine Study Group Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury